Alaunos Therapeutics, Inc. (TCRT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Alaunos Therapeutics, Inc. (TCRT) Healthcare & Pipeline Overview

Alaunos Therapeutics, Inc. specializes in developing personalized adoptive T-cell receptor therapies for oncology, leveraging its proprietary technology to target specific tumor mutations, positioning itself as a key player in the clinical-stage biotechnology landscape.

What Is the Investment Thesis for TCRT?

Alaunos Therapeutics, Inc. represents a unique investment opportunity in the oncology sector, focusing on personalized T-cell receptor therapies that address significant unmet medical needs in cancer treatment. The company’s TCR Library, currently in Phase I/II trials, targets mutations present in a variety of cancers, potentially leading to significant market penetration as these therapies advance through clinical stages. The partnerships with esteemed institutions like MD Anderson Cancer Center and the National Cancer Institute provide credibility and enhance research capabilities, potentially accelerating development timelines. However, investors should be aware of the risks associated with clinical-stage biotech firms, including trial failures and regulatory hurdles that could impact the company’s future valuation. Monitoring upcoming trial results and regulatory updates will be crucial for assessing the company's trajectory.

Based on FMP financials and quantitative analysis

TCRT Key Highlights

Market Cap of $4.59M indicates a focus on early-stage development with no current revenue.

• Profit Margin of -136966.7% reflects significant investment in R&D typical for clinical-stage biotech.
• Gross Margin of -6333.3% is indicative of early-stage operations with no revenue generation.
• Beta of -1.06 suggests lower volatility compared to the market, a characteristic of clinical-stage biotech firms.
• No dividend yield as the company reinvests all resources into R&D for future therapies.

Who Are TCRT's Competitors?

TCRT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TCRT's Key Strengths?

Innovative TCR technology platform for personalized cancer therapies.

• Strong collaborations with leading research institutions.
• Focused approach on solid tumors with significant unmet needs.

What Are TCRT's Weaknesses?

Limited financial resources with no current revenue.

• High dependency on clinical trial outcomes for future success.
• Small workforce may limit operational capabilities.

What Could Drive TCRT Stock Higher?

Results from Phase I/II clinical trials for the TCR Library expected in late 2026.

• Strategic collaborations with MD Anderson Cancer Center and National Cancer Institute enhancing research capabilities.
• Potential licensing agreements for TCR therapies as clinical trials progress.

What Are the Key Risks for TCRT?

Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.

• Regulatory hurdles could delay clinical trial approvals.
• High dependency on successful clinical trial outcomes.
• Competitive pressures from other biotech firms developing similar therapies.

What Are the Growth Opportunities for TCRT?

• Growth opportunity 1: The global cancer therapeutics market is projected to grow at a CAGR of 7.5% from 2020 to 2025, creating a significant opportunity for Alaunos's TCR therapies. As the company advances its TCR Library through clinical trials, successful outcomes could lead to accelerated market entry and capture of a share in this expanding market.
• Growth opportunity 2: Alaunos's hunTR platform focuses on human neoantigen T-cell receptors, which represent a novel approach in cancer immunotherapy. The neoantigen-targeting therapy market is expected to grow significantly, with increasing recognition of the importance of personalized medicine in oncology, potentially leading to partnerships and collaborations that enhance the company's market position.
• Growth opportunity 3: The strategic collaborations with leading institutions like MD Anderson Cancer Center provide access to cutting-edge research and clinical expertise. This collaboration could facilitate faster clinical trial progress and improve the likelihood of successful outcomes, positioning Alaunos favorably against competitors in the oncology space.
• Growth opportunity 4: The ongoing advancements in CAR-T cell therapies and TCR technologies are paving the way for innovative treatment options. Alaunos's focus on TCR-engineered therapies could allow the company to capitalize on this trend, particularly as regulatory bodies become more supportive of novel cancer treatments.
• Growth opportunity 5: As awareness of personalized cancer therapies increases, Alaunos could benefit from heightened interest and investment in its clinical programs. The potential for breakthrough therapies in oncology could attract partnerships with larger pharmaceutical companies, enhancing funding and development resources.

What Threats Does TCRT Face?

• High competition in the biotechnology and oncology sectors.
• Regulatory hurdles that could delay clinical trials.
• Risk of clinical trial failures impacting reputation and funding.

What Are TCRT's Competitive Advantages?

• Proprietary TCR technology platform that differentiates its therapies from competitors.
• Strong partnerships with leading cancer research institutions enhance credibility.
• Focus on personalized medicine positions the company favorably in the oncology market.
• Innovative approaches to targeting tumor mutations may lead to breakthrough therapies.
• Clinical-stage focus allows for adaptability in response to emerging market needs.

What Does TCRT Do?

Founded as ZIOPHARM Oncology, Inc., Alaunos Therapeutics, Inc. rebranded in January 2022 to reflect its focus on oncology and T-cell receptor (TCR) engineered therapies. Headquartered in Houston, Texas, the company is dedicated to developing personalized cancer treatments through its innovative TCR technology platform. Alaunos is currently in the clinical trial phase, with a robust pipeline that includes a TCR Library undergoing Phase I/II trials, featuring ten T-cell receptors aimed at targeting mutated KRAS, TP53, and EGFR across various cancers, including non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also advancing its hunTR platform, which concentrates on human neoantigen T-cell receptors, and mbIL-15, designed for solid tumor treatment. Strategic collaborations enhance its research capabilities, including a licensing agreement with PGEN Therapeutics, Inc., a partnership with The University of Texas MD Anderson Cancer Center, and a patent licensing and R&D agreement with the National Cancer Institute. As a clinical-stage company, Alaunos faces the challenges typical of biotech firms, including the inherent risks of clinical trial outcomes and regulatory approvals, but its innovative approach positions it well within the competitive landscape of cancer therapies.

What Products and Services Does TCRT Offer?

• Develop adoptive T-cell receptor (TCR) engineered therapies for cancer treatment.
• Focus on personalized medicine by targeting individual patient tumor mutations.
• Conduct clinical trials to evaluate the safety and efficacy of TCR therapies.
• Maintain strategic collaborations with research institutions and biotech firms.
• Advance innovative platforms such as hunTR and mbIL-15 for solid tumor treatment.
• Target a range of cancers including non-small cell lung, colorectal, and pancreatic cancers.

How Does TCRT Make Money?

• Generate revenue through partnerships and collaborations with research institutions.
• Focus on licensing agreements to leverage proprietary technology.
• Seek funding through grants and strategic partnerships for R&D.
• Develop therapies that may be commercialized upon successful clinical trials.
• Potential future revenue from product sales upon regulatory approval.

What Industry Does TCRT Operate In?

The biotechnology industry is experiencing robust growth, driven by advancements in personalized medicine and innovative therapies. Within this landscape, Alaunos Therapeutics, Inc. is positioned to leverage its proprietary TCR technology to address significant gaps in current cancer treatments, particularly for solid tumors. The competitive landscape includes established biotech firms and emerging startups, all vying for market share in a rapidly evolving sector.

Who Are TCRT's Key Customers?

• Oncology patients seeking personalized cancer treatment options.
• Healthcare providers and oncologists interested in innovative therapies.
• Research institutions collaborating on clinical trials and studies.
• Pharmaceutical companies looking for licensing opportunities.
• Investors and stakeholders interested in biotechnology advancements.

Over the past six months, Alaunos Therapeutics, Inc. insiders filed 6 SEC Form 4 transactions — 0 sales and 6 purchases. On net that is roughly 34K shares acquired (about $84K) — insiders putting money in tends to read as conviction.

TCRT Valuation & Market Position

With a $4.59M market cap, Alaunos Therapeutics, Inc. sits in the micro-cap segment of the market. Relative to its peer group, TCRT's quantitative score of 16/100 is below the peer average of 58/100.

Key Financial Metrics

Its free cash flow yield is -66.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.63 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -105.4%, the inverse of the P/E and a quick read on earnings relative to price.

Alaunos Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Wall Street analysts project Alaunos Therapeutics, Inc. revenue of about $87.5M for fiscal 2026, with EPS near $-21.00.

Company Profile

Alaunos Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Fort Lauderdale, US. The company is led by CEO Holger Weis. TCRT has traded publicly since 2005.

TCRT Financials

TCRT Latest News

TCRT Analyst Consensus

TCRT MoonshotScore

Alaunos Therapeutics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources